D1-Receptor, DARPP-32, and PP-1 in the primate Corpus luteum and luteinized granulosa cells: Evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin

Artur Mayerhofer, Stephanie Fritz, Robert Grünert, Sheryl L. Sanders, Diane M. Duffy, Sergio Ojeda, Richard Stouffer

    Research output: Contribution to journalArticle

    24 Citations (Scopus)

    Abstract

    The multifunctional phosphoprotein "dopamine and cAMP-related phosphoprotein, Mr 32,000" (DARPP-32), which is able to act as an intracellular third messenger, was previously found to be present in human luteinized granulosa cells (GCs) and human ovary. DARPP-32 phosphorylation in GCs was increased by dopamine (DA) acting via a DA-1 receptors (D1-R). In the present study, we examined whether the major endocrine signaling molecule for GCs, LH/human CG (hCG), could also affect DARPP-32 phosphorylation. Immunoprecipitation studies showed that hCG, as well as DA, increased phosphorylation of DARPP-32 at threonine residues within 10 min, indicating that the signal transduction pathways of a hormone and a neurotransmitter involve DARPP-32 in GCs. Phosphorylated DARPP-32 is known to inhibit a cellular phosphatase (PP-1), which was also found to be expressed by GCs. Using RT-PCR and sequence analyses we showed that DARPP-32, PP-1, and D1-R genes were not restricted to cultured luteinized GCs, but were expressed in vivo, in the corpus luteum (CL) of the rhesus monkey throughout its entire life span. Whereas hCG increased steroid production in monkey luteinized GCs and in isolated luteal cells, DA failed to affect basal or hCG-stimulated progesterone production. This indicates that, unlike the LH/hCG receptor, the D1-R is not directly linked to steroid production. Although the precise role of D1-R in the CL remains to be shown, the presence of D1-R, DARPP-32, and its target PP-1 in this endocrine tissue, as well as the phosphorylation of DARPP-32 by a gonadotropin and by DA in luteinized GCs, indicate that the signal transduction pathways of the neurotransmitter DA and the gonadotropin hCG/LH involve DARPP-32. The PP-1 inhibitor DARPP-32 may, thus, be a third messenger used by both DA and hCG/LH to exert common regulatory influences on the cells of the CL.

    Original languageEnglish (US)
    Pages (from-to)4750-4757
    Number of pages8
    JournalJournal of Clinical Endocrinology and Metabolism
    Volume85
    Issue number12
    DOIs
    StatePublished - 2000

    Fingerprint

    Dopamine D1 Receptors
    Phosphorylation
    Granulosa Cells
    Phosphoproteins
    Corpus Luteum
    Chorionic Gonadotropin
    Primates
    Dopamine
    Signal transduction
    Dopamine Receptors
    Gonadotropins
    Neurotransmitter Agents
    Signal Transduction
    Steroids
    Cyclic AMP Receptors
    Luteal Cells
    Threonine

    ASJC Scopus subject areas

    • Biochemistry
    • Endocrinology, Diabetes and Metabolism

    Cite this

    D1-Receptor, DARPP-32, and PP-1 in the primate Corpus luteum and luteinized granulosa cells : Evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin. / Mayerhofer, Artur; Fritz, Stephanie; Grünert, Robert; Sanders, Sheryl L.; Duffy, Diane M.; Ojeda, Sergio; Stouffer, Richard.

    In: Journal of Clinical Endocrinology and Metabolism, Vol. 85, No. 12, 2000, p. 4750-4757.

    Research output: Contribution to journalArticle

    @article{6fe113214e0547728708d66c7f64c4d2,
    title = "D1-Receptor, DARPP-32, and PP-1 in the primate Corpus luteum and luteinized granulosa cells: Evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin",
    abstract = "The multifunctional phosphoprotein {"}dopamine and cAMP-related phosphoprotein, Mr 32,000{"} (DARPP-32), which is able to act as an intracellular third messenger, was previously found to be present in human luteinized granulosa cells (GCs) and human ovary. DARPP-32 phosphorylation in GCs was increased by dopamine (DA) acting via a DA-1 receptors (D1-R). In the present study, we examined whether the major endocrine signaling molecule for GCs, LH/human CG (hCG), could also affect DARPP-32 phosphorylation. Immunoprecipitation studies showed that hCG, as well as DA, increased phosphorylation of DARPP-32 at threonine residues within 10 min, indicating that the signal transduction pathways of a hormone and a neurotransmitter involve DARPP-32 in GCs. Phosphorylated DARPP-32 is known to inhibit a cellular phosphatase (PP-1), which was also found to be expressed by GCs. Using RT-PCR and sequence analyses we showed that DARPP-32, PP-1, and D1-R genes were not restricted to cultured luteinized GCs, but were expressed in vivo, in the corpus luteum (CL) of the rhesus monkey throughout its entire life span. Whereas hCG increased steroid production in monkey luteinized GCs and in isolated luteal cells, DA failed to affect basal or hCG-stimulated progesterone production. This indicates that, unlike the LH/hCG receptor, the D1-R is not directly linked to steroid production. Although the precise role of D1-R in the CL remains to be shown, the presence of D1-R, DARPP-32, and its target PP-1 in this endocrine tissue, as well as the phosphorylation of DARPP-32 by a gonadotropin and by DA in luteinized GCs, indicate that the signal transduction pathways of the neurotransmitter DA and the gonadotropin hCG/LH involve DARPP-32. The PP-1 inhibitor DARPP-32 may, thus, be a third messenger used by both DA and hCG/LH to exert common regulatory influences on the cells of the CL.",
    author = "Artur Mayerhofer and Stephanie Fritz and Robert Gr{\"u}nert and Sanders, {Sheryl L.} and Duffy, {Diane M.} and Sergio Ojeda and Richard Stouffer",
    year = "2000",
    doi = "10.1210/jc.85.12.4750",
    language = "English (US)",
    volume = "85",
    pages = "4750--4757",
    journal = "Journal of Clinical Endocrinology and Metabolism",
    issn = "0021-972X",
    publisher = "The Endocrine Society",
    number = "12",

    }

    TY - JOUR

    T1 - D1-Receptor, DARPP-32, and PP-1 in the primate Corpus luteum and luteinized granulosa cells

    T2 - Evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin

    AU - Mayerhofer, Artur

    AU - Fritz, Stephanie

    AU - Grünert, Robert

    AU - Sanders, Sheryl L.

    AU - Duffy, Diane M.

    AU - Ojeda, Sergio

    AU - Stouffer, Richard

    PY - 2000

    Y1 - 2000

    N2 - The multifunctional phosphoprotein "dopamine and cAMP-related phosphoprotein, Mr 32,000" (DARPP-32), which is able to act as an intracellular third messenger, was previously found to be present in human luteinized granulosa cells (GCs) and human ovary. DARPP-32 phosphorylation in GCs was increased by dopamine (DA) acting via a DA-1 receptors (D1-R). In the present study, we examined whether the major endocrine signaling molecule for GCs, LH/human CG (hCG), could also affect DARPP-32 phosphorylation. Immunoprecipitation studies showed that hCG, as well as DA, increased phosphorylation of DARPP-32 at threonine residues within 10 min, indicating that the signal transduction pathways of a hormone and a neurotransmitter involve DARPP-32 in GCs. Phosphorylated DARPP-32 is known to inhibit a cellular phosphatase (PP-1), which was also found to be expressed by GCs. Using RT-PCR and sequence analyses we showed that DARPP-32, PP-1, and D1-R genes were not restricted to cultured luteinized GCs, but were expressed in vivo, in the corpus luteum (CL) of the rhesus monkey throughout its entire life span. Whereas hCG increased steroid production in monkey luteinized GCs and in isolated luteal cells, DA failed to affect basal or hCG-stimulated progesterone production. This indicates that, unlike the LH/hCG receptor, the D1-R is not directly linked to steroid production. Although the precise role of D1-R in the CL remains to be shown, the presence of D1-R, DARPP-32, and its target PP-1 in this endocrine tissue, as well as the phosphorylation of DARPP-32 by a gonadotropin and by DA in luteinized GCs, indicate that the signal transduction pathways of the neurotransmitter DA and the gonadotropin hCG/LH involve DARPP-32. The PP-1 inhibitor DARPP-32 may, thus, be a third messenger used by both DA and hCG/LH to exert common regulatory influences on the cells of the CL.

    AB - The multifunctional phosphoprotein "dopamine and cAMP-related phosphoprotein, Mr 32,000" (DARPP-32), which is able to act as an intracellular third messenger, was previously found to be present in human luteinized granulosa cells (GCs) and human ovary. DARPP-32 phosphorylation in GCs was increased by dopamine (DA) acting via a DA-1 receptors (D1-R). In the present study, we examined whether the major endocrine signaling molecule for GCs, LH/human CG (hCG), could also affect DARPP-32 phosphorylation. Immunoprecipitation studies showed that hCG, as well as DA, increased phosphorylation of DARPP-32 at threonine residues within 10 min, indicating that the signal transduction pathways of a hormone and a neurotransmitter involve DARPP-32 in GCs. Phosphorylated DARPP-32 is known to inhibit a cellular phosphatase (PP-1), which was also found to be expressed by GCs. Using RT-PCR and sequence analyses we showed that DARPP-32, PP-1, and D1-R genes were not restricted to cultured luteinized GCs, but were expressed in vivo, in the corpus luteum (CL) of the rhesus monkey throughout its entire life span. Whereas hCG increased steroid production in monkey luteinized GCs and in isolated luteal cells, DA failed to affect basal or hCG-stimulated progesterone production. This indicates that, unlike the LH/hCG receptor, the D1-R is not directly linked to steroid production. Although the precise role of D1-R in the CL remains to be shown, the presence of D1-R, DARPP-32, and its target PP-1 in this endocrine tissue, as well as the phosphorylation of DARPP-32 by a gonadotropin and by DA in luteinized GCs, indicate that the signal transduction pathways of the neurotransmitter DA and the gonadotropin hCG/LH involve DARPP-32. The PP-1 inhibitor DARPP-32 may, thus, be a third messenger used by both DA and hCG/LH to exert common regulatory influences on the cells of the CL.

    UR - http://www.scopus.com/inward/record.url?scp=0034485864&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0034485864&partnerID=8YFLogxK

    U2 - 10.1210/jc.85.12.4750

    DO - 10.1210/jc.85.12.4750

    M3 - Article

    C2 - 11134138

    AN - SCOPUS:0034485864

    VL - 85

    SP - 4750

    EP - 4757

    JO - Journal of Clinical Endocrinology and Metabolism

    JF - Journal of Clinical Endocrinology and Metabolism

    SN - 0021-972X

    IS - 12

    ER -